Media stories about Icon (NASDAQ:ICLR) have trended somewhat positive recently, according to Accern. The research firm ranks the sentiment of press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Icon earned a media sentiment score of 0.18 on Accern’s scale. Accern also gave headlines about the medical research company an impact score of 47.4788578162716 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

Several analysts have recently commented on the stock. KeyCorp increased their price target on shares of Icon from $130.00 to $152.00 and gave the company an “overweight” rating in a research note on Monday, June 18th. SunTrust Banks increased their price target on shares of Icon to $153.00 and gave the company a “buy” rating in a research note on Thursday, July 26th. BidaskClub cut shares of Icon from a “buy” rating to a “hold” rating in a research note on Thursday. Robert W. Baird reissued a “buy” rating and set a $154.00 price target on shares of Icon in a research note on Thursday, July 26th. Finally, Zacks Investment Research raised shares of Icon from a “sell” rating to a “hold” rating in a research note on Tuesday, May 8th. Three research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $143.60.

ICLR opened at $147.56 on Friday. Icon has a one year low of $101.22 and a one year high of $149.69. The company has a current ratio of 2.10, a quick ratio of 2.10 and a debt-to-equity ratio of 0.28. The company has a market cap of $7.86 billion, a PE ratio of 27.38, a P/E/G ratio of 2.07 and a beta of 0.40.

Icon (NASDAQ:ICLR) last announced its quarterly earnings data on Wednesday, July 25th. The medical research company reported $1.31 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.48 by ($0.17). Icon had a net margin of 13.69% and a return on equity of 26.35%. The business had revenue of $641.60 million during the quarter, compared to the consensus estimate of $618.64 million. During the same period in the previous year, the business posted $1.34 earnings per share. Icon’s revenue was up 48.9% compared to the same quarter last year. equities analysts anticipate that Icon will post 6.08 EPS for the current fiscal year.

Icon Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.

Read More: What do investors mean by earnings per share?

Insider Buying and Selling by Quarter for Icon (NASDAQ:ICLR)

Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with's FREE daily email newsletter.